Summary

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

Age: All ages

Gender: All

Start Date: 06/23/2014

Primary Completion Date (Estimated): 06/30/2032

Study Completion Date (Estimated): 06/30/2032

Accepts Healthy Volunteers: No

Trial Purpose and Description

Eligibility Criteria

Age: All ages

Gender: All

Accepts Healthy Volunteers: No

Inclusion criteria:

1. Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS).

2. Signed informed consent and medical records release by the participant or a legally acceptable representative

3. Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.

Exclusion criteria:

1. Participants currently participating in a blinded clinical trial or their extension studies.

2. Participants who have never been on PN/IV support.

3. Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.